Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat

Psychopharmacology

Volumn 139, Issue 4, 1998, Pages 356-363

  Aravagiri, Manickam ^a   Yuwiler, Arthur ^b   Marder, Stephen R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

9 Hydroxy risperidone; Antipsychotics; Brain to plasma level ratio; Dose tissue level relationship; Rat; Regional brain distribution; Risperidone; Tissue distribution

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; ISOXAZOLES; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; TISSUE DISTRIBUTION;

EID: 0031717385     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050726     Document Type: Article

References (24)

1. Aravagiri M, Marder SR, Yuwiler A, Midha KK, Kula NS, Baldessarini RJ (1995) Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 13:235-247
2. Aravagiri M, Marder SR, Yuwiler A (1996) Pharmacokinetics of risperidone and its 9-hydroxy metabolite in brain and other tissues of rat after oral dose of risperidone. Pharm Res 13:S467
3. Aravagiri M, Marder SR, Ames D, Wirshing WC (1998) Plasma concentration of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry (in press)
4. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
5. Blin O, Michel J, Bouthours P (1996) Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 16:38-44
6. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15:24S-29S
7. Chouinard G (1995) Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15:36S-44S
8. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:19S-23S
9. Hansch C, Sammes PG, Taylor JB (1990) Comprehensive Medicinal Chemistry. The rational design, mechanistic study & therapeutic application of chemical compounds, vol 6. Pergamon Press, Oxford
10. 2 receptors. Int Clin Psychopharmacol 10:19-30
11. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Janssen AAI, Zylicz Z, Visscher HW, Jonkman JHG (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268
12. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
13. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
14. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G (1995) Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17:402-412
15. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heyknats J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1141
16. Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114:9-23
17. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J (1994) The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos 22: 129-138
18. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 119:345-348
19. 2 receptor occupancy studies and clinical response. Br J Psychiatr 168 [Suppl 29]:40-44
20. Schotte A, Jansssen PFM, Gommeren W, Luyten WHML, van Gompel P, Lesage AS, de Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 134:57-73
21. Sunderland T, Cohen BM (1986) Blood to brain distribution of neuroleptics. Psychiatry Res 20:299-305
22. Swendsen CN, Bird ED (1986) HPLC with electrochemical detection to measure chloropromazine, thioridazine, and metabolites in human brain. Psychopharmacology 90:316-321
23. Tsuneizumi T, Babb SM, Cohen BM (1992) Drug distribution between blood and brain as determinant of antipsychotic drug effects. Biol Psychiatry 32:817-824
24. Van Beijsterveldt LEC, Geerts RJF, Leysen JE, Megens AAHP, Van den Eynde HMJ, Meuldermans WEG, Heykants JJP (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114:53-62